Aytu BioPharma (NASDAQ:AYTU) Downgraded by Zacks Research to “Strong Sell”

Zacks Research downgraded shares of Aytu BioPharma (NASDAQ:AYTU) from a hold rating to a strong sell rating in a report published on Monday morning,Zacks reports.

Several other analysts have also issued reports on the company. Citigroup reissued a “positive” rating on shares of Aytu BioPharma in a report on Tuesday, September 22nd. Weiss Ratings raised Aytu BioPharma from a “sell (d-)” rating to a “sell (d)” rating in a research note on Tuesday, September 22nd. Finally, Ascendiant Capital Markets lifted their price objective on Aytu BioPharma from $14.00 to $14.50 and gave the company a “buy” rating in a research report on Thursday, June 11th. Two research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Aytu BioPharma currently has a consensus rating of “Hold” and an average price target of $14.50.

Aytu BioPharma Trading Up 0.5%

NASDAQ:AYTU opened at $2.05 on Monday. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.13 and a quick ratio of 1.00. The firm has a market capitalization of $22.28 million, a price-to-earnings ratio of -1.23 and a beta of 0.17. Aytu BioPharma has a one year low of $1.80 and a one year high of $3.07. The business has a fifty day moving average price of $2.22 and a 200-day moving average price of $2.30.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in Aytu BioPharma in the 2nd quarter worth $49,000. Persistent Asset Partners Ltd bought a new position in shares of Aytu BioPharma in the second quarter worth about $82,000. Dimensional Fund Advisors LP grew its position in shares of Aytu BioPharma by 23.3% during the first quarter. Dimensional Fund Advisors LP now owns 43,585 shares of the company’s stock worth $119,000 after purchasing an additional 8,222 shares in the last quarter. Arete Wealth Advisors LLC purchased a new stake in shares of Aytu BioPharma during the first quarter worth about $135,000. Finally, Crown Advisors Management Inc. bought a new stake in Aytu BioPharma during the 2nd quarter valued at approximately $430,000. Institutional investors own 33.49% of the company’s stock.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on commercializing prescription medicines, primarily for pediatric and primary-care markets. The company’s activities include acquiring, developing and commercializing products intended to address unmet needs in areas such as attention deficit hyperactivity disorder (ADHD), allergies and other common medical conditions.

Aytu’s ADHD portfolio has included Adzenys XR-ODT, an orally disintegrating extended-release amphetamine tablet; Cotempla XR-ODT, an orally disintegrating extended-release methylphenidate tablet; and Dyanavel XR, an extended-release liquid amphetamine formulation.